Impact of vitamin d dose on biochemical parameters in patients with secondary hyperparathyroidism receiving cinacalcet

Nephron - Clinical Practice

Volumn 112, Issue 1, 2009, Pages

  Wilkie, Martin ^a   Pontoriero, Giuseppe ^b   MacÁrio, Fernando ^c   Yaqoob, Magdi ^d   Bouman, Koen ^e   Braun, Johann ^f   Von Albertini, Beat ^g   Brink, Hans ^h   Maduell, Francisco ⁱ   Graf, Helmut ^j   Frazão, João M ^k   Bos, Willem Jan ^l   Torregrosa, Vicente ^m   Saha, Heikki ⁿ   Reichel, Helmut ^o   Zani, Valter J ^p   Carter, Dave ^q   Messa, Piergiorgio ^r  

^a SHEFFIELD TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b A MANZONI HOSPITAL   (Italy)

^c Gambro Healthcare ^*  (Portugal)

^d ROYAL LONDON HOSPITAL   (United Kingdom)

^e ZNA Middelheim   (Belgium)

^f KfH Kuratorium für Dialyse and Nierentransplantation E V   (Germany)

^g Centre de Dialyse Cecil   (Sweden)

^h MEDISCH SPECTRUM TWENTE   (Netherlands)

ⁱ HOSPITAL GENERAL DE CASTELLÓN   (Spain)

^j Krankenanstalt der Stadt Wien Rudolfstiftung   (Austria)

^k UNIVERSITY OF PORTO   (Portugal)

^l ST ANTONIUS HOSPITAL   (Netherlands)

^m HOSPITAL CLÍNIC   (Spain)

ⁿ TAMPERE UNIVERSITY HOSPITAL   (Finland)

^o Nephrological Center   (Germany)

^p AMGEN INC   (United States)

^q AMGEN LTD   (United Kingdom)

^r Nephrology Division   (Italy)

more..

Author keywords

Calcimimetic; Calcium; Calcium phosphorus product; Cinacalcet; Parathyroid hormone; Phosphorus; Secondary hyperparathyroidism; Vitamin D

Indexed keywords

ALFACALCIDOL; CALCITRIOL; CALCIUM; CINACALCET; PARATHYROID HORMONE; PARICALCITOL; PHOSPHORUS; VITAMIN D;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERABILITY; HEMODIALYSIS PATIENT; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SECONDARY HYPERPARATHYROIDISM;

ADULT; CALCIUM; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYPERCALCEMIA; HYPERPARATHYROIDISM, SECONDARY; HYPERPHOSPHATEMIA; KIDNEY FAILURE, CHRONIC; MALE; NAPHTHALENES; PARATHYROID HORMONE; PHOSPHORUS; RENAL DIALYSIS; VITAMIN D;

EID: 64149117771     PISSN: 16602110     EISSN: None     Source Type: Journal    
DOI: 10.1159/000212102     Document Type: Article

References (17)

1. Slatopolsky E, Brown A, Dusso A: Pathogenesis of secondary hyperparathyroidism. Kidney Int Suppl 1999;73:S14-S19.
2. Slatopolsky E, Delmez JA: Pathogenesis of secondary hyperparathyroidism. Am J Kidney Dis 1994;23:229-236.
3. Rix M, Andreassen H, Eskildsen P, Langdahl B, Olgaard K: Bone mineral density and biochemical markers of bone turnover in patients with predialysis chronic renal failure. Kidney Int 1999;56:1084-1093.
4. Salem MM: Hyperparathyroidism in the hemodialysis population: a survey of 612patients. Am J Kidney Dis 1997;29:862-865.
5. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM: Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004;15:2208-2218.
6. Young EW, Albert JM, Satayathum S, Goodkin DA, Pisoni RL, Akiba T, Akizawa T, Kurokawa K, Bommer J, Piera L, Port FK: Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2005;67:1179-1187.
7. Wald R, Sarnak MJ, Tighiouart H, Cheung AK, Levey AS, Eknoyan G, Miskulin DC: Disordered mineral metabolism in hemodialysis patients: an analysis of cumulative effects in the Hemodialysis (HEMO) Study. Am J Kidney Dis 2008;52:531-540.
8. Kalantar-Zadeh K, Kuwae N, Regidor DL, Kovesdy CP, Kilpatrick RD, Shinaberger CS, McAllister CJ, Budoff MJ, Salusky IB, Kopple JD: Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006;70:771-780.
9. Moe SM, Drueke TB: Management of secondary hyperparathyroidism: the importance and the challenge of controlling parathyroid hormone levels without elevating calcium, phosphorus, and calcium-phosphorus product. Am J Nephrol 2003;23:369-379.
10. Walling MW: Intestinal Ca and phosphate transport: differential responses to vitamin D3metabolites. Am J Physiol 1977;233: E488-E494.
11. Block GA, Port FK: Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am J Kidney Dis 2000;35:1226-1237.
12. Nemeth EF, Heaton WH, Miller M, Fox J, Balandrin MF, Van Wagenen BC, Colloton M, Karbon W, Scherrer J, Shatzen E, Rishton G, Scully S, Qi M, Harris R, Lacey D, Martin D: Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl. J Pharmacol Exp Ther 2004;308:627-635.
13. Lindberg JS, Culleton B, Wong G, Borah MF, Clark RV, Shapiro WB, Roger SD, Husserl FE, Klassen PS, Guo MD, Albizem MB, Coburn JW: Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. J Am Soc Nephrol 2005;16:800-807.
14. Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, Hercz G, Cunningham J, Abu-Alfa AK, Messa P, Coyne DW, Locatelli F, Cohen RM, Evenepoel P, Moe SM, Fournier A, Braun J, Mc-Cary LC, Zani VJ, Olson KA, Drüeke TB, Goodman WG: Cinacalcet for secondary hyperparathyroidism in patients receiving hemodia lysis. N Engl J Med 2004;350:1516-1525.
15. Messa P, Macário F, Yaqoob M, Bouman K, Braun J, von Albertini B, Brink H, Maduell F, Graf H, Frazão JM, Bos WJ, Torregrosa V, Saha H, Reichel H, Wilkie M, Zani VJ, Molemans B, Carter D, Locatelli F: The OPTIMA Study: assessing a new cinacalcet (Sensipar®/Mimpara®) treatment algorithm for secondary hyperparathyroidism. Clin J Am Soc Nephrol 2008;3:36-45.
16. Young EW, Akiba T, Albert JM, McCarthy JT, Kerr PG, Mendelssohn DC, Jadoul M: Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2004;44(suppl 2):34-38.
17. Foley RN, Parfrey PS, Harnett JD, Kent GM, Hu L, O'Dea R, Murray DC, Barre PE: Hypocalcemia, morbidity, and mortality in end-stage renal disease. Am J Nephrol 1996;16:386-393.